Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Appendiceal Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT07472517 2026-05-12

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Phase 3 Recruiting

670 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04152499 2026-05-11

MK-2870-001

Phase 1/2 Active not recruiting

1,410 enrolled

BreastGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT06257264 2026-05-11

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase 1 Recruiting

258 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06646276 2026-05-11

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

530 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05363280 2026-05-08

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Phase 2 Recruiting

80 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Small Cell Lung Carcinoma

NCT05963867 2026-05-08

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

Phase 1 Recruiting

12 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07296809 2026-05-08

SKB500 Combinations in Patients With Small Cell Lung Cancer

Phase 2 Recruiting

80 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

288 enrolled

CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT07325136 2026-05-07

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Recruiting

240 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

157 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT07559929 2026-05-06

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.

Phase 1/2 Not yet recruiting

200 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07006727 2026-05-05

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Phase 1 Recruiting

116 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05815160 2026-05-04

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Terminated

34 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT07559019 2026-04-30

Safety and Preliminary Activity of BI115 in Advanced SCLC

Phase 1 Not yet recruiting

150 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04702880 2026-04-29

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

Phase 2 Completed

135 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06117774 2026-04-29

DeLLphi-306

Phase 3 Active not recruiting

404 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07488923 2026-04-29

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Phase 1 Not yet recruiting

110 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05879978 2026-04-28

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase 1 Active not recruiting

45 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07231445 2026-04-28

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Phase 1 Recruiting

100 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05882058 2026-04-27

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Phase 2 Recruiting

204 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04745689 2026-04-24

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Thoracic

Small Cell Lung Carcinoma

NCT06736418 2026-04-24

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

Phase 1 Active not recruiting

17 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07177937 2026-04-24

A Study of DXC014 in Patients With Advanced Solid Tumors.

Phase 1 Recruiting

150 enrolled

DermatologicGenitourinaryThoracic

Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT07550842 2026-04-24

A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Phase 1 Not yet recruiting

33 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03043872 2026-04-22

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 1 FDA

Thoracic

Small Cell Lung Carcinoma

NCT06586957 2026-04-21

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Recruiting

150 enrolled

BreastGastrointestinalGynecologicThoracic

Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Uterine Diseases, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

KEYNOTE-B98

DAREONᵀᴹ-8

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

MK 7339-013

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

DeLLphi-312

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

DeLLphi-313

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

(DeLLphi-310)

ALBORAN

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

SEZanne

IMFINZI-subQ

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

DLLEVATE

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

MK-2870-001

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

SKB500 Combinations in Patients With Small Cell Lung Cancer

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

PF-07104091 as a Single Agent and in Combination Therapy

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Safety and Preliminary Activity of BI115 in Advanced SCLC

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

DeLLphi-306

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

TAZMAN

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

A Study of DXC014 in Patients With Advanced Solid Tumors.

A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

CASPIAN

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

MEDIOLA